Veterinary Excipients Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Application (Biologics, Pharmaceuticals, Medicated Feed Additives), By Chemical Group (Polymers, Alcohols, Lipids, Mineral Salts, Others), By Animal Type (Production Animals, Companion Animals), By End Use (Solubilizers/ Solvents, Binders, Stabilizers, Coating, Diluents & fillers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.11 Billion
CAGR (2026-2031)	4.82%
Fastest Growing Segment	Production Animals
Largest Market	North America
Market Size (2031)	USD 2.81 Billion

Market Overview

The Global Veterinary Excipients Market will grow from USD 2.11 Billion in 2025 to USD 2.81 Billion by 2031 at a 4.82% CAGR. Veterinary excipients are pharmacologically inactive substances formulated alongside active pharmaceutical ingredients in animal health products to enhance drug stability, bioavailability, and palatability. The market is primarily propelled by the rising global demand for animal-derived protein and a significant surge in companion animal ownership, which necessitates advanced therapeutic solutions. Additionally, the growing prevalence of zoonotic diseases has accelerated the need for effective veterinary formulations, further stimulating the demand for functional excipients. According to the American Pet Products Association, in 2024, total U.S. pet industry expenditures reached $152 billion, reflecting the robust financial commitment of owners to animal welfare that underpins this sector's growth.

Despite these favorable conditions, the market faces a significant impediment regarding stringent and divergent regulatory frameworks across different regions. Manufacturers must navigate complex compliance standards established by bodies such as the FDA and EMA, which can prolong development timelines and increase production costs. This regulatory complexity acts as a substantial barrier to entry for new excipients, potentially stifling innovation and limiting the availability of cost-effective solutions in emerging markets where veterinary standards are still evolving.

Key Market Drivers

Rising Global Pet Ownership and Humanization Trends are fundamentally reshaping the veterinary excipients landscape by accelerating the demand for sophisticated oral solid dosage forms and palatable delivery systems. As pet owners increasingly view their companions as family members, there is a distinct shift toward treating chronic conditions such as arthritis and diabetes, necessitating long-term medication adherence. This trend compels manufacturers to utilize advanced functional excipients, particularly taste-masking agents and disintegrants, to transform traditional veterinary drugs into pet-friendly chewables and treats. The financial commitment to advanced veterinary care is evident in the surging insurance sector; according to the North American Pet Health Insurance Association, April 2024, in the 'State of the Industry Report 2024', the total premium volume for pet insurance in North America reached a record $4.27 billion in 2023, signaling a robust market for premium pharmaceutical formulations.

The Expansion of Intensive Livestock Farming Operations serves as a parallel driver, creating high-volume demand for cost-effective excipients used in vaccines, medicated feed additives, and injectables. To maintain productivity and food security within densely populated herds, producers rely heavily on prophylactic treatments, where excipients act as critical stabilizers and carriers to ensure drug efficacy under field conditions. This reliance is underscored by production forecasts; according to the USDA Foreign Agricultural Service, October 2024, in the 'Livestock and Poultry: World Markets and Trade' report, global chicken meat exports are forecast to rise to a record 13.8 million tons in 2025, reflecting the intense pressure on production systems that sustains the bulk excipient market. The immense scale of pharmaceutical requirements in this sector is further highlighted by leading manufacturers; according to Zoetis, in 2024, the company reported full-year revenue of $8.5 billion for 2023, illustrating the substantial industrial footprint requiring a steady supply of pharmaceutical ingredients.

Download Free Sample Report

Key Market Challenges

The stringent and fragmented regulatory landscape across different regions constitutes a primary obstacle hampering the growth of the Global Veterinary Excipients Market. Manufacturers must adhere to disparate compliance requirements enforced by agencies such as the FDA and EMA, which often necessitates extensive and redundant validation processes for excipient safety and efficacy. This regulatory divergence significantly escalates production costs and prolongs development timelines, thereby reducing the speed at which novel excipients can be integrated into finished veterinary formulations. These elevated resource demands act as a substantial barrier to entry, disproportionately affecting smaller enterprises and stifling the overall rate of innovation within the industry.

Furthermore, the complexity of securing regulatory approval limits the availability of advanced therapeutic options in key markets where cost-efficiency is paramount. The inability to rapidly deploy compliant formulations directly affects the productivity of end-use sectors that rely heavily on accessible veterinary medicines. According to Animal Medicines Australia, in 2024, the livestock industry was forecast to contribute $37.6 billion to agricultural production, a figure that highlights the critical economic volume dependent on the efficient approval and supply of high-quality animal health products. Consequently, regulatory inefficiencies not only hinder market expansion but also threaten the economic stability of the industries these excipients serve.

Key Market Trends

The development of high-purity excipients is accelerating due to the rapid expansion of the veterinary biologics sector, particularly for monoclonal antibodies and large-molecule vaccines. Unlike traditional small-molecule drugs, these complex formulations require specialized stabilizing agents, such as pharmaceutical-grade surfactants, buffers, and cryoprotectants, to maintain efficacy during freeze-drying and storage. This technical necessity is driving significant capital expenditure in manufacturing capabilities designed specifically to handle sensitive biological ingredients, distinct from standard chemical production. According to Merck Animal Health, May 2025, in the press release 'Merck Animal Health and State of Kansas Announce $895 Million Investment', the company committed $895 million to expand its De Soto, Kansas facility, specifically enhancing filling and freeze-drying capacity for biologics and vaccines.

Concurrently, the market is witnessing a fundamental shift toward sustainable and biodegradable excipients, compelled by the rigorous environmental, social, and governance (ESG) mandates of leading animal health corporations. Manufacturers are increasingly scrutinizing their supply chains to reduce Scope 3 emissions, prioritizing ingredients derived from renewable sources over petrochemical-based polymers to minimize their environmental impact. This industry-wide decarbonization strategy creates a cascading requirement for excipient suppliers to validate the carbon footprint and biodegradability of their portfolios to remain compliant with major procurement standards. According to Zoetis, June 2025, in the '2024 Sustainability Progress Update', the company reported sourcing 80.6% of its global electricity from renewable sources, illustrating the scale of the green transition that is reshaping procurement criteria for pharmaceutical ingredients.

Segmental Insights

The production animals segment is emerging as the fastest-growing category within the global veterinary excipients market, driven by the escalating global demand for high-quality animal protein. This trend necessitates rigorous disease management and prevention strategies among livestock producers to ensure food security and efficient production. Consequently, there is a growing requirement for specialized excipients that enhance the stability and delivery of mass-administered veterinary drugs. Additionally, regulatory frameworks established by entities like the European Medicines Agency continue to uphold stringent standards for food safety, further fueling the adoption of compliant ingredients in livestock healthcare.

Regional Insights

North America maintains a leading position in the Global Veterinary Excipients Market, attributed to its established animal healthcare infrastructure and significant investment in veterinary medicine. The region benefits from high pet ownership rates and a strong focus on livestock health, which drive the demand for reliable drug formulations. Additionally, the United States Food and Drug Administration, specifically the Center for Veterinary Medicine, provides a clear regulatory pathway for product approvals. This structured environment encourages manufacturers to develop compliant and effective veterinary products, thereby solidifying the region's dominance in the global sector.

Recent Developments

• In September 2025, Gattefossé inaugurated its new manufacturing facility in Lufkin, Texas, marking a major milestone in its international industrial expansion. The plant, which had achieved key quality certifications earlier in the year, specializes in the production of lipid-based specialty ingredients for the pharmaceutical and personal care industries. This development is of considerable importance to the Global Veterinary Excipients Market, as the facility is dedicated to serving both human and animal health sectors in North America and beyond. The local production capacity aims to secure the supply chain for lipid excipients, which are increasingly used to improve the bioavailability and stability of veterinary formulations.
• In May 2025, Roquette Frères completed the acquisition of IFF Pharma Solutions, a division of International Flavors & Fragrances Inc., to reinforce its leadership in the pharmaceutical and nutraceutical sectors. This strategic move significantly expanded the company's portfolio of polymer excipients, including cellulosics and other plant-based ingredients essential for oral dosage forms. The integration of these assets is expected to strengthen the company's capabilities in the Global Veterinary Excipients Market by offering a broader range of drug delivery solutions for animal health applications. The acquisition aligns with the company's strategy to rebalance its portfolio towards high-value health and nutrition markets.
• In September 2024, Evonik Industries AG commenced operations at its new spray drying facility for aqueous dispersions of polymers at its site in Darmstadt, Germany. This expansion was designed to meet the increasing demand for functional excipients used in oral drug delivery solutions, catering to both the human and animal health markets. The new facility, which operates using green electricity, allows the company to improve supply security and shorten delivery times for its enteric coating systems. This development directly impacts the Global Veterinary Excipients Market by enhancing the availability of high-quality polymers required for veterinary solid dosage forms and controlled-release formulations.
• In March 2024, Croda International Plc entered into a strategic partnership with the Access to Advanced Health Institute (AAHI) to advance the development of novel adjuvant formulations. This collaboration aimed to leverage the combined expertise of both organizations to make innovative vaccine adjuvant systems globally accessible, thereby supporting the creation of robust and durable vaccines. The partnership is particularly relevant to the Global Veterinary Excipients Market, as adjuvants are critical components in veterinary vaccine formulations, enhancing immune responses in livestock and companion animals. By combining manufacturing capabilities with research innovation, the companies sought to address key challenges in vaccine delivery for both human and animal health sectors.

Key Market Players

• Croda International plc
• JRS PHARMA GmbH + Co. KG
• Colorcon
• Quality Chemicals S.L
• IOI Oleo GmbH
• Lipoid GmbH
• Gattefossé SAS
• Azelis Group
• Ashland Global Holdings Inc.
• Spectrum Chemical Mfg. Corp.

By Application	By Chemical Group	By Animal Type	By End Use	By Region
Biologics Pharmaceuticals Medicated Feed Additives	Polymers Alcohols Lipids Mineral Salts Others	Production Animals Companion Animals	Solubilizers/ Solvents Binders Stabilizers Coating Diluents & fillers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Excipients Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Excipients Market, By Application:

• Biologics
• Pharmaceuticals
• Medicated Feed Additives

• Veterinary Excipients Market, By Chemical Group:

• Polymers
• Alcohols
• Lipids
• Mineral Salts
• Others

• Veterinary Excipients Market, By Animal Type:

• Production Animals
• Companion Animals

• Veterinary Excipients Market, By End Use:

• Solubilizers/ Solvents
• Binders
• Stabilizers
• Coating
• Diluents & fillers
• Others

• Veterinary Excipients Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE